Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

WEGOVY (semaglutide) injection, for subcutaneous use — Highlights of Prescribing Information

United States Food and Drug Administration. FDA Approved Labeling 2024

Document identifier
CEI-BR-025
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
United States Food and Drug Administration
Title
WEGOVY (semaglutide) injection, for subcutaneous use — Highlights of Prescribing Information
Source
FDA Approved Labeling
Year
2024
Volume, issue, pages
Reference ID revision 01/2024
Digital object identifier
not held by the Institute
PubMed identifier
not held by the Institute
Record type
Regulatory document
Institute identifier
CEI-BR-025

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

DocumentSeries
Monograph: SemaglutideCompound monograph
Monograph: Semaglutide, oralCompound monograph
Monograph: LiraglutideCompound monograph
3 citing documents.

§1.3Subject tags

semaglutide label fda

Compound Evidence Institute · CEI-BR-025 · https://compoundevidence.com/bibliography/fdawegovy/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.